Literature DB >> 29732377

Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study.

Alice Y Guh1, Susan Hocevar Adkins1, Qunna Li1, Sandra N Bulens1, Monica M Farley2,3,4, Zirka Smith3,4,5, Stacy M Holzbauer6,7, Tory Whitten6, Erin C Phipps8, Emily B Hancock8, Ghinwa Dumyati9, Cathleen Concannon9, Marion A Kainer10, Brenda Rue10, Carol Lyons11, Danyel M Olson11, Lucy Wilson12, Rebecca Perlmutter12, Lisa G Winston13, Erin Parker14, Wendy Bamberg15, Zintars G Beldavs16, Valerie Ocampo16, Maria Karlsson1, Dale N Gerding17,18, L Clifford McDonald1.   

Abstract

BACKGROUND: An increasing proportion of Clostridium difficile infections (CDI) in the United States are community-associated (CA). We conducted a case-control study to identify CA-CDI risk factors.
METHODS: We enrolled participants from 10 US sites during October 2014-March 2015. Case patients were defined as persons age ≥18 years with a positive C. difficile specimen collected as an outpatient or within 3 days of hospitalization who had no admission to a health care facility in the prior 12 weeks and no prior CDI diagnosis. Each case patient was matched to one control (persons without CDI). Participants were interviewed about relevant exposures; multivariate conditional logistic regression was performed.
RESULTS: Of 226 pairs, 70.4% were female and 52.2% were ≥60 years old. More case patients than controls had prior outpatient health care (82.1% vs 57.9%; P < .0001) and antibiotic (62.2% vs 10.3%; P < .0001) exposures. In multivariate analysis, antibiotic exposure-that is, cephalosporin (adjusted matched odds ratio [AmOR], 19.02; 95% CI, 1.13-321.39), clindamycin (AmOR, 35.31; 95% CI, 4.01-311.14), fluoroquinolone (AmOR, 30.71; 95% CI, 2.77-340.05) and beta-lactam and/or beta-lactamase inhibitor combination (AmOR, 9.87; 95% CI, 2.76-340.05),-emergency department visit (AmOR, 17.37; 95% CI, 1.99-151.22), white race (AmOR 7.67; 95% CI, 2.34-25.20), cardiac disease (AmOR, 4.87; 95% CI, 1.20-19.80), chronic kidney disease (AmOR, 12.12; 95% CI, 1.24-118.89), and inflammatory bowel disease (AmOR, 5.13; 95% CI, 1.27-20.79) were associated with CA-CDI.
CONCLUSIONS: Antibiotics remain an important risk factor for CA-CDI, underscoring the importance of appropriate outpatient prescribing. Emergency departments might be an environmental source of CDI; further investigation of their contribution to CDI transmission is needed.

Entities:  

Keywords:  community-associated Clostridium difficile infection

Year:  2017        PMID: 29732377      PMCID: PMC5903408          DOI: 10.1093/ofid/ofx171

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


  35 in total

1.  Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.

Authors:  Vanessa Stevens; Ghinwa Dumyati; Jack Brown; Edwin Wijngaarden
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-08-10       Impact factor: 2.890

2.  Incidence of Clostridium difficile infection in inflammatory bowel disease.

Authors:  Joseph F Rodemann; Erik R Dubberke; Kimberly A Reske; Da Hea Seo; Christian D Stone
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

3.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

4.  Control of an outbreak of diarrhoea in a vascular surgery unit caused by a high-level clindamycin-resistant Clostridium difficile PCR ribotype 106.

Authors:  L Ratnayake; J McEwen; N Henderson; D Nathwani; G Phillips; D Brown; J Coia
Journal:  J Hosp Infect       Date:  2011-08-23       Impact factor: 3.926

5.  Evaluation of hospital room assignment and acquisition of Clostridium difficile infection.

Authors:  Megan K Shaughnessy; Renee L Micielli; Daryl D DePestel; Jennifer Arndt; Cathy L Strachan; Kathy B Welch; Carol E Chenoweth
Journal:  Infect Control Hosp Epidemiol       Date:  2011-03       Impact factor: 3.254

6.  A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.

Authors:  Susanna Naggie; Becky A Miller; Kimberly B Zuzak; Brian W Pence; Ashley J Mayo; Bradly P Nicholson; Preeta K Kutty; L Clifford McDonald; Christopher W Woods
Journal:  Am J Med       Date:  2011-03       Impact factor: 4.965

7.  Contamination of ready-to-eat raw vegetables with Clostridium difficile in France.

Authors:  Catherine Eckert; Béatrice Burghoffer; Frédéric Barbut
Journal:  J Med Microbiol       Date:  2013-02-28       Impact factor: 2.472

8.  Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.

Authors:  C R Clabots; S Johnson; M M Olson; L R Peterson; D N Gerding
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

9.  New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration.

Authors:  Michelle M Merrigan; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  Int J Antimicrob Agents       Date:  2009-03       Impact factor: 5.283

10.  Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.

Authors:  Preeta K Kutty; Christopher W Woods; Arlene C Sena; Stephen R Benoit; Susanna Naggie; Joyce Frederick; Sharon Evans; Jeffery Engel; L Clifford McDonald
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

View more
  25 in total

1.  Body mass index and risk of clostridioides difficile infection: a systematic review and meta-analysis.

Authors:  Nipith Charoenngam; Ben Ponvilawan; Jerapas Thongpiya; Pitchaporn Yingchoncharoen; Thanat Chaikijurajai; Natapat Chaisidhivej; Caroline M Apovian; Patompong Ungprasert
Journal:  Infection       Date:  2022-01-05       Impact factor: 3.553

2.  Clinical Determinants Predicting Clostridioides difficile Infection among Patients with Chronic Kidney Disease.

Authors:  Łukasz Lis; Andrzej Konieczny; Michał Sroka; Anna Ciszewska; Kornelia Krakowska; Tomasz Gołębiowski; Zbigniew Hruby
Journal:  Antibiotics (Basel)       Date:  2022-06-08

3.  Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.

Authors:  Alice Y Guh; Yi Mu; Lisa G Winston; Helen Johnston; Danyel Olson; Monica M Farley; Lucy E Wilson; Stacy M Holzbauer; Erin C Phipps; Ghinwa K Dumyati; Zintars G Beldavs; Marion A Kainer; Maria Karlsson; Dale N Gerding; L Clifford McDonald
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

4.  Effectiveness of Outpatient Antibiotics After Surgical Drainage of Abscesses in Reducing Treatment Failure.

Authors:  Michael S Pulia; Rebecca J Schwei; Brian W Patterson; Michael D Repplinger; Maureen A Smith; Manish N Shah
Journal:  J Emerg Med       Date:  2018-08-24       Impact factor: 1.484

Review 5.  Clostridioides difficile Infection.

Authors:  Alice Y Guh; Preeta K Kutty
Journal:  Ann Intern Med       Date:  2018-10-02       Impact factor: 25.391

6.  Mechanisms of Colonization Resistance Against Clostridioides difficile.

Authors:  Colleen M Pike; Casey M Theriot
Journal:  J Infect Dis       Date:  2021-06-16       Impact factor: 5.226

7.  Attitudes toward using clinical decision support in community pharmacies to promote antibiotic stewardship.

Authors:  Sena J Sayood; Margaret Botros; Katie J Suda; Randi Foraker; Michael J Durkin
Journal:  J Am Pharm Assoc (2003)       Date:  2021-04-15

8.  Patterns of dental antibiotic prescribing in 2017: Australia, England, United States, and British Columbia (Canada).

Authors:  Wendy Thompson; Leanne Teoh; Colin C Hubbard; Fawziah Marra; David M Patrick; Abdullah Mamun; Allen Campbell; Katie J Suda
Journal:  Infect Control Hosp Epidemiol       Date:  2021-04-05       Impact factor: 6.520

Review 9.  Epidemiology of community-acquired and recurrent Clostridioides difficile infection.

Authors:  Yichun Fu; Yuying Luo; Ari M Grinspan
Journal:  Therap Adv Gastroenterol       Date:  2021-05-22       Impact factor: 4.409

10.  Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection.

Authors:  Malin Inghammar; Henrik Svanström; Marianne Voldstedlund; Mads Melbye; Anders Hviid; Kåre Mølbak; Björn Pasternak
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.